دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Core outcome set implementation supported by the BJD
E.C. Veysey, J.R. Ingram, C.J. Apfelbacher, A.M. Drucker
doi : 10.1111/bjd.20050
Volume184, Issue6,Pages 987-989
Evidence is lacking for or against palmoplantar pustulosis treatments: what does this mean for the clinician
S.R. Feldman, W.W. Huang
doi : 10.1111/bjd.19658
Volume184, Issue6,Pages 990-990
Incompletely excised keratinocyte carcinomas: more common than once thought?
J. Guckian, N. Rajan, N. Kibbi
doi : 10.1111/bjd.20049
Volume184, Issue6,Pages 991-991
Head-to-head comparison of biologics in psoriasis: better acceleration does not necessarily win all races
L. Puig
doi : 10.1111/bjd.19696
Volume184, Issue6,Pages 992-993
Epidemiology of cutaneous lymphoma
M. Vermeer
doi : 10.1111/bjd.19829
Volume184, Issue6,Pages 993-994
Cutaneous lymphomas (CLs) represent a rare and heterogeneous group of lymphomas that present in the skin without extracutaneous manifestations at the time of diagnosis. As the diagnosis and classification of CLs requires integration of clinical, histological, immunophenotypical and molecular characteristics, and is complicated by the rareness of these diseases, clinical care of patients with a CL is often concentrated in national expert centres. Data on the epidemiology of CLs are primarily based on patient cohorts seen in these expert centres and in national pathology registries. However, patient cohorts from expert centres can be influenced by referral bias, while pathology registries are prone to misclassification of patients as central review with the integration of clinical and pathological features is not routinely performed. However, an accurate understanding of the incidence and the prevalence of CLs is important for clinicians, patients, pharma and regulatory policymakers.
The underestimated risk for complications in immunocompetent patients with herpes zoster: should we change our clinical practice?
K. Kridin, A.D. Cohen
doi : 10.1111/bjd.19860
Volume184, Issue6,Pages 994-995
Divergent pathways for melanoma: what is the role of genetics?
R. Ghiasvand
doi : 10.1111/bjd.19887
Volume184, Issue6,Pages 995-996
The ecological approach to biologic drugs: survival of the fittest
R. Gniadecki
doi : 10.1111/bjd.20053
Volume184, Issue6,Pages 996-997
Classifying the severity of bullous pemphigoid disease
C. Blome, T.M. Klein
doi : 10.1111/bjd.19830
Volume184, Issue6,Pages 997-998
Bullous pemphigoid disease (BPD) is a relatively rare autoimmune disorder with an estimated incidence of 4 per 100 000 person years in the UK; the incidence sharply increases with age.1 Disease severity can be determined by the number of newly occurring blisters per day, with 10 or more indicating high severity.2 However, about 20% of people with BPD have a nonbullous appearance of the disease at the time of diagnosis;2 they present with urticarial, erythematous, eczematous skin lesions. This is why defining severity by number of blisters alone may misclassify these patients.
Advancing novel therapies for ichthyoses
M. Schmuth, J. Reichelt, R. Gruber
doi : 10.1111/bjd.19698
Volume184, Issue6,Pages 998-999
Sequencing technology increasingly allows for clarification of the genetic basis of disease pathogenesis in rare genodermatoses such as the ichthyoses. While there has been great progress in the discovery of genetic variations underlying ichthyoses and the elucidation of the pathomechanisms, therapeutic developments have been sparse. Too often, no therapeutic benefit follows from research advances in the field, and, to date, there are few examples for targeted therapy that address the molecular cause of the disease. Thus, patient options are still mostly limited to keratolytics, topical anti-inflammatory agents, rather unspecific emollient therapies, and topical and systemic retinoids.
Regulatory noncoding RNAs help protect keratinocytes from ultraviolet-mediated damage in vitiligo
C. Cotter, M. Kretz, N. Rajan
doi : 10.1111/bjd.19827
Volume184, Issue6,Pages 999-1000
The importance of keratinocyte–dendritic cell interactions in understanding fragrance allergy
S.M. Pilkington
doi : 10.1111/bjd.19828
Volume184, Issue6,Pages 1000-1001
Pathogenic role of ST18 in pemphigus vulgaris
T. Hashimoto
doi : 10.1111/bjd.19883
Volume184, Issue6,Pages 1001-1002
Expanding the use of allogeneic haematopoietic cell transplantation in dermatology
J.W. Bauer
doi : 10.1111/bjd.19682
Volume184, Issue6,Pages 1002-1003
Epidermolysis bullosa (EB) comprises a group of rare, genetically determined skin fragility disorders characterized by (muco)cutaneous blistering following mild mechanical trauma. The most severe clinical symptoms occur in patients affected by mutations in genes coding for type VII collagen and the subchains of laminin 332. In these patients, mainly mutations leading to protein chain termination result in disease manifestations in the bronchopulmonary, gastrointestinal, urogenital and ophthalmic systems in addition to the skin.1
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils
S. Narla, M. Azzam, S. Townsend, G. Vellaichamy, A.V. Marzano, A. Alavi, M.A. Lowes, I.H. Hamzavi
doi : 10.1111/bjd.19538
Volume184, Issue6,Pages 1004-1013
Applications and future directions for optical coherence tomography in dermatology*
B. Wan, C. Ganier, X. Du-Harpur, N. Harun, F.M. Watt, R. Patalay, M.D. Lynch
doi : 10.1111/bjd.19553
Volume184, Issue6,Pages 1014-1022
Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments
G. Obeid, G. Do, L. Kirby, C. Hughes, E. Sbidian, L. Le Cleach
doi : 10.1111/bjd.19560
Volume184, Issue6,Pages 1023-1032
Incomplete surgical excision of keratinocyte skin cancers: a systematic review and meta-analysis*
G.S. Nolan, A.L. Kiely, J.P. Totty, J.C.R. Wormald, R.G. Wade, M. Arbyn, A. Jain
doi : 10.1111/bjd.19660
Volume184, Issue6,Pages 1033-1044
Relationship between body mass index and atopic dermatitis: a Mendelian randomization approach in exploring causality: a critical appraisal
C.X. Pan, Y.-H. Jee, K.J. Moore, P. Kraft, M.M. Asgari
doi : 10.1111/bjd.19702
Volume184, Issue6,Pages 1045-1046
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*
A. Blauvelt, C. Leonardi, B. Elewski, J.J. Crowley, L.C. Guenther, M. Gooderham, R.G. Langley, R. Vender, A. Pinter, C.E.M. Griffiths, Y. Tada, H. Elmaraghy, R.G. Lima, G. Gallo, L. Renda, R. Burge, S.Y. Park, B. Zhu, K. Papp, on behalf of the IXORA-R Study Group
doi : 10.1111/bjd.19509
Volume184, Issue6,Pages 1047-1058
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*
G. Dobos, A. de Masson, C. Ram-Wolff, M. Beylot-Barry, A. Pham-Ledard, N. Ortonne, S. Ingen-Housz-Oro, M. Battistella, M. d’Incan, J. Rouanet, F. Franck, M.D. Vignon-Pennamen, N. Franck, A. Carlotti, S. Boulinguez, L. Lamant, T. Petrella, S. Dalac, P. Joly, P. Courville, J. Rivet, O. Dereure, F. Amatore, S. Taix, F. Grange, A. Durlach, G. Quéreux, N. Josselin, I. Moulonguet, L. Mortier, R. Dubois, E. Maubec, L. Laroche, L. Michel, I. Templier, S. Barete, C. Nardin, O. Augereau, B. Vergier, M. Bagot, the French Study Group on Cutaneous Lymphomas (GFELC)
doi : 10.1111/bjd.19644
Volume184, Issue6,Pages 1059-1067
Association between air pollution and atopic dermatitis in Guangzhou, China: modification by age and season*
H.L. Wang, J. Sun, Z.M. Qian, Y.Q. Gong, J.B. Zhong, R.D. Yang, C.L. Wan, S.Q. Zhang, D.F. Ning, H. Xian, J.J. Chang, C.J. Wang, E. Shacham, J.Q. Wang, H.L. Lin
doi : 10.1111/bjd.19645
Volume184, Issue6,Pages 1068-1076
Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data*
H.J. Forbes, K. Bhaskaran, D. Grint, V.H. Hu, S.M. Langan, H.I. McDonald, C. Morton, L. Smeeth, J.L. Walker, C. Warren-Gash
doi : 10.1111/bjd.19687
Volume184, Issue6,Pages 1077-1084
Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity*
R. Laskar, A. Ferreiro-Iglesias, D.T. Bishop, M.M. Iles, P.A. Kanetsky, B.K. Armstrong, M.H. Law, A.M. Goldstein, J.F. Aitken, G.G. Giles, Australian Melanoma Family Study Investigators, Leeds Case–Control Study Investigators, H.A. Robbins, A.E. Cust
doi : 10.1111/bjd.19705
Volume184, Issue6,Pages 1085-1093
Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis*
T. Graier, W. Salmhofer, C. Jonak, W. Weger, C. K?lli, B. Gruber, P.G. Sator, K. Prillinger, A. Mlynek, M. Schütz-Bergmayr, L. Richter, G. Ratzinger, C. Painsi, S. Selhofer, N. H?ring, K. Wippel-Slupetzky, H. Skvara, H. Trattner, A. Tanew, M. Inzinger, R. Tatarski, C. Bangert, C. Ellersdorfer, R. Lichem, A. Gruber-Wackernagel, A. Hofer, F. Legat, E. Schmiedberger, R. Strohal, B. Lange-Asschenfeldt, M. Schmuth, I. Vujic, W. Hoetzenecker, F. Trautinger, W. Saxinger, R. Müllegger, F. Quehenberger, P. Wolf
doi : 10.1111/bjd.19701
Volume184, Issue6,Pages 1094-1105
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid*
W. Masmoudi, M. Vaillant, S. Vassileva, A. Patsatsi, G. Quereux, C. Moltrasio, C. Abasq, C. Prost-Squarcioni, D. Kottler, D. Kiritsi, N. Litrowski, P. Plantin, L. Friedrichsen, A. Zebrowska, S. Duvert-Lehembre, S. Hofmann, V. Ferranti, F. Jouen, P. Joly, V. Hebert, the EADV Autoimmune Bullous Skin Disease Task Force
doi : 10.1111/bjd.19611
Volume184, Issue6,Pages 1106-1112
Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*
K.A. Reynolds, D.I. Schlessinger, A.F. Yanes, V. Godinez-Puig, B.R. Chen, A.O. Kurta, J.K. Cotseones, S.G. Chiren, S. Iyengar, S.A. Ibrahim, B.Y. Kang, B. Worley, R. Behshad, D.M. DeHoratius, P. Denes, A.M. Drucker, L.M. Dzubow, J.R. Etzkorn, C.A. Harwood, J.Y.S. Kim, N. Lawrence, E.H. Lee, G.S. Lissner, A.A. Marghoob, A. Guminiski, R.N. Matin, A.R. Mattox, B.B. Mittal, J.R. Thomas, X.A. Zhou, D. Zloty, B.G.M. Hughes, M.K. Nottage, A.C. Green, A.A.E. Testori, G. Argenziano, C. Longo, I. Zalaudek, C. Lebbe, J. Malvehy, P. Saiag, S.S. Cernea, J. Schmitt, J.J. Kirkham, E. Poon, J.F. Sobanko, T.V. Cartee, I.A. Maher, M. Alam
doi : 10.1111/bjd.19693
Volume184, Issue6,Pages 1113-1122
Development of a pathogenesis-based therapy for peeling skin syndrome type 1*
F. Valentin, H. Wiegmann, T. Tarinski, H. Nikolenko, H. Traupe, E. Liebau, M. Dathe, V. Oji
doi : 10.1111/bjd.19546
Volume184, Issue6,Pages 1123-1131
The long noncoding RNA MALAT1 suppresses miR-211 to confer protection from ultraviolet-mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1*
H.D. Brahmbhatt, R. Gupta, A. Gupta, S. Rastogi, R. Misri, A. Mobeen, A. Ghosh, P. Kothari, S. Sitaniya, V. Scaria, A. Singh
doi : 10.1111/bjd.19666
Volume184, Issue6,Pages 1132-1142
Skin sensitization to fragrance hydroperoxides: interplay between dendritic cells, keratinocytes and free radicals
J. Lichter, M. Silva e Sousa, N. Peter, F. Sahli, B. Vileno, S. Kuresepi, C. Gourlaouen, E. Giménez-Arnau, B. Bl?meke
doi : 10.1111/bjd.19685
Volume184, Issue6,Pages 1143-1152
ST18 affects cell–cell adhesion in pemphigus vulgaris in a tumour necrosis factor-?-dependent fashion*
S. Assaf, L. Malki, T. Mayer, J. Mohamad, A. Peled, M. Pavlovsky, K. Malovitski, O. Sarig, D. Vodo, E. Sprecher
doi : 10.1111/bjd.19679
Volume184, Issue6,Pages 1153-1160
Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds*
C.L. Ebens, J.A. McGrath, J.A. Riedl, A.R. Keith, G. Lilja, S. Rusch, D.R. Keene, S.F. Tufa, M.J. Riddle, R. Shanley, A.E. Van Heest, J. Tolar
doi : 10.1111/bjd.19503
Volume184, Issue6,Pages 1161-1169
GGCX mutations in a patient with overlapping pseudoxanthoma elasticum/cutis laxa-like phenotype
D. Li, E. Ryu, A.H. Saeidian, L. Youssefian, E. Oliphant, S.F. Terry, P.L. Tong, J. Uitto, N.K. Haass, Q. Li
doi : 10.1111/bjd.19576
Volume184, Issue6,Pages 1170-1174
Ultraviolet index and sun safety: are we all on the same page?
A.M. Chacko, F. Lagacé, F. Jafarian
doi : 10.1111/bjd.19620
Volume184, Issue6,Pages 1175-1176
Clinical photography in skin of colour: tips and best practices
J.C. Lester, L. Clark Jr, E. Linos, R. Daneshjou
doi : 10.1111/bjd.19811
Volume184, Issue6,Pages 1177-1179
Multifocal myositis and elevated creatine phosphokinase associated with the use of ustekinumab for hidradenitis suppurativa
J. Smith, N. Ezekwe, A. Pourang, I. Hamzavi
doi : 10.1111/bjd.19762
Volume184, Issue6,Pages 1181-1182
Planning slow Mohs excision margins for lentigo maligna: a retrospective nonrandomized cohort study comparing reflectance confocal microscopy margin mapping vs. visual inspection with dermoscopy
J. M. Gao, J. J. Garioch, M. Fadhil, E. Tan, N. Shah, M. Moncrieff
doi : 10.1111/bjd.19764
Volume184, Issue6,Pages 1182-1183
Obstructive sleep apnoea in psoriasis and hidradenitis suppurativa
A. Kelly, J. Meurling, S. Kirthi Jeyarajah, C. Ryan, R. Hughes, J. Garvey, B. Kirby
doi : 10.1111/bjd.19802
Volume184, Issue6,Pages 1183-1185
Targeting the expression of T antigens with selinexor (KPT-330) shows promise for Merkel cell polyomavirus-positive Merkel cell carcinoma treatment
R. Gupta, R.A. Simonette, H.Q. Doan, P.L. Rady, S.K. Tyring
doi : 10.1111/bjd.19801
Volume184, Issue6,Pages 1185-1187
COVID-19-associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role?
I. Abad?as-Granado, A. Navarro-Bielsa, A.M. Morales-Callaghan, L. Roc, C.C. Suso-Est?valez, M. Povar-Echeverr?a, Y. Gilaberte
doi : 10.1111/bjd.19806
Volume184, Issue6,Pages 1187-1190
Identification of compound heterozygous mutations in AP1B1 leading to the newly described recessive keratitis–ichthyosis–deafness (KIDAR) syndrome
J. Vornweg, S. Gl?ser, M. Ahmad-Anwar, A.D. Zimmer, M. Kuhn, S. H?rer, G.C. Korenke, J. Grothaus, H. Ott, J. Fischer
doi : 10.1111/bjd.19815
Volume184, Issue6,Pages 1190-1192
Development or exacerbation of hidradenitis suppurativa in two transgender men after initiation of testosterone therapy
M. Buonomo, M.D. Mansh, D. Thorpe, N. Goldfarb
doi : 10.1111/bjd.19812
Volume184, Issue6,Pages 1192-1194
SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19
E. Welsh, J.A. Cardenas-de la Garza, A. Cuellar-Barboza, R. Franco-Marquez, R.I. Arvizu-Rivera
doi : 10.1111/bjd.19833
Volume184, Issue6,Pages 1194-1195
Agminated benign vascular tumour successfully treated with trametinib
S. Greenberger, R. Stein, A. Ollech, M.E. Hartstein, O. Benyamini, M. Yalon, A. Levi, M. Lapidoth, A. Barzilai
doi : 10.1111/bjd.19814
Volume184, Issue6,Pages 1195-1197
Minimal, superficial DNA damage in human skin from filtered far-ultraviolet C
R.P. Hickerson, M.J. Conneely, S.K. Hirata Tsutsumi, K. Wood, D.N. Jackson, S.H. Ibbotson, E. Eadie
doi : 10.1111/bjd.19816
Volume184, Issue6,Pages 1197-1199
Inducible skin-associated lymphoid tissue (iSALT) in a patient with Schnitzler syndrome who manifested wheals on recurrent localized erythema
H. Kamido, D. Shimomiya, T. Kogame, R. Takimoto-Ito, T.R. Kataoka, M. Hirata, C. Ueshima, A. Otsuka, F.M. Ghazawi, T. Nomura, N. Kambe, K. Kabashima
doi : 10.1111/bjd.19808
Volume184, Issue6,Pages 1199-1201
Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis
K. Tascilar, O. Bayindir, A. Dogru, I. Tinazzi, G. Kimyon, C. Ozisler, A. Erden, E. Dalkilic, G.Y. Cetin, S. Y?lmaz, D. Solmaz, S. Bakirci, A. Omma, T. Kasifoglu, O. Kucuksahin, M. Cinar, L. Kilic, M. Can, E.F. Tarhan, E. Bilgin, E.D. Ersozlu, T. Duruoz, S. Yavuz, S. Pehlevan, M.A. Tufan, E. Gonullu, F. Yildiz, S.E. Esmen, A. Kucuk, A. Tufan, A. Balkarli, R. Mercan, V. Yazisiz, S. Erten, S. Akar, K. Aksu, S.Z. Aydin, U. Kalyoncu
doi : 10.1111/bjd.19826
Volume184, Issue6,Pages 1202-1203
Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument
C. C. Zouboulis
doi : 10.1111/bjd.19798
Volume184, Issue6,Pages 1203-1204
Huriez syndrome caused by a large deletion that abrogates the skin-specific isoform of SMARCAD1
A.Y.T. Loh, C.M. Ho, S. Muthiah, B. Venkatesh, S. Zwolinski, A.P.J.J. Bray, B. Reversade, N. Rajan, T.J. Carney
doi : 10.1111/bjd.19799
Volume184, Issue6,Pages 1205-1207
Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality
C. Bernigaud, D. Guillemot, A. Ahmed-Belkacem, L. Grimaldi-Bensouda, A. Lespine, F. Berry, L. Softic, C. Chenost, G. Do-Pham, B. Giraudeau, S. Fourati, O. Chosidow
doi : 10.1111/bjd.19821
Volume184, Issue6,Pages 1207-1209
Linear and disseminated porokeratosis in one family showing identical and independent second hits in MVD among skin lesions, respectively: a proof-of-concept study
C. Shiiya, S. Aoki, K. Nakabayashi, K. Hata, M. Amagai, A. Kubo
doi : 10.1111/bjd.19824
Volume184, Issue6,Pages 1209-1212
Telescope punch biopsy of normal-appearing skin to diagnose intravascular lymphoma
M.C.G. Winge, D.J. Iberri, R.A. Novoa, B.Y. Kwong, L.C. Zaba
doi : 10.1111/bjd.19711
Volume184, Issue6,Pages e194-e194
Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab
J. Hugo, M. Arenbergerova, P. Arenberger, S. Gkalpakiotis
doi : 10.1111/bjd.19835
Volume184, Issue6,Pages e195-e195
Measuring the success of treatments for squamous cell cancer of the skin
doi : 10.1111/bjd.20100
Volume184, Issue6,Pages e196-e196
Squamous cell carcinoma (SCC) of the skin is the second most common skin cancer. Over half a million cases are diagnosed in the USA and UK each year. There are several ways to treat SCC of the skin, including different types of medications and surgery.
Development of a protein replacement therapy for peeling skin syndrome
doi : 10.1111/bjd.20101
Volume184, Issue6,Pages e197-e197
Peeling skin syndrome type 1 is a severe form of congenital ichthyosis. Patients have severe itch and generalized peeling of the skin. Current therapeutic approaches are very unsatisfactory. The disease is the result of mutations (mistakes) in the CDSN gene, which cause a lack of the protein corneodesmosin (CDSN) in the skin.
Defining mild, moderate and severe bullous pemphigoid
doi : 10.1111/bjd.20102
Volume184, Issue6,Pages e198-e198
Bullous pemphigoid is a rare chronic disease with blistering and itch. The Bullous Pemphigoid Disease Area Index (BPDAI) is a new scoring system developed to measure bullous pemphigoid activity.
Air pollution may trigger atopic dermatitis
doi : 10.1111/bjd.20103
Volume184, Issue6,Pages e199-e199
Atopic dermatitis (also known as atopic eczema) is a common inflammatory skin disease characterized by intense itch. Approximately 20% of children and 3% of adults are affected by this skin disease worldwide, and the number of individuals with it has increased threefold in industrialized nations since the 1970s. Although occurring primarily during childhood, atopic dermatitis has become more common in Chinese adults in recent years, potentially because of interactions between genetic and environment factors.
Chronic wounds in patients with epidermolysis bullosa who have had bone marrow transplantation can be healed by skin grafts from the same donor
doi : 10.1111/bjd.20104
Volume184, Issue6,Pages e200-e200
Epidermolysis bullosa (EB) is a group of genetic disorders with abnormally fragile skin. Recessive dystrophic EB (RDEB) is a particular subtype in which the skin lacks type VII collagen and cannot form anchoring fibrils essential for skin integrity. Blisters turn into painful, scarring wounds that persist and recur despite standard treatments. Skin grafting using the patient’s own skin does not solve the problem, and healthy donor skin is rejected. Better treatments are needed.
Comparison of two new treatments for psoriasis
doi : 10.1111/bjd.20105
Volume184, Issue6,Pages e201-e201
Psoriasis is a skin disease that affects about 125 million people worldwide, causing scaly and itchy patches of skin all over the body. One-quarter of people with psoriasis also have nail psoriasis, which causes abnormally coloured and misshapen nails.
Looking into the skin with optical coherence tomography
doi : 10.1111/bjd.20106
Volume184, Issue6,Pages e202-e202
Most skin problems are diagnosed by their naked eye appearance. Recently, hand-held magnifiers (dermatoscopes) have been introduced to aid diagnosis. More accurate diagnosis often requires taking a skin sample and looking at it under a microscope. A number of modern, non-invasive optical imaging techniques are being developed to potentially facilitate diagnosis. One of these is optical coherence tomography (OCT).
Different pathways for developing melanoma by body site
doi : 10.1111/bjd.20107
Volume184, Issue6,Pages e203-e203
Melanoma is a form of cancer that can develop anywhere on the skin. It is the third most common invasive cancer in Australia and the fifth most common in the UK. Risk factors include sun exposure, skin type, hair colour, moles and genetic factors. However, there may be different pathways for how melanoma develops in a person depending on where the melanoma occurs. This means that the degree to which these risk factors cause melanoma may vary across different sites on the body.
Understanding why patients with vitiligo rarely develop skin cancers
doi : 10.1111/bjd.20108
Volume184, Issue6,Pages e204-e204
Vitiligo is a common skin disorder affecting 0·2–2% of the world’s population. It occurs because of the loss of cells (melanocytes) responsible for producing melanin (the pigment that gives skin its characteristic colour) resulting in the affected skin appearing milky white. The presence of melanin pigment acts as a barrier to the harmful, cancer-inducing sun’s rays [ultraviolet (UV) radiation]. However, surprisingly, despite the loss of melanin, people with vitiligo rarely develop skin cancers. This study from India aimed to find out the reason why.
The impact of the release of new biologic treatments for psoriasis on discontinuation of existing treatment
doi : 10.1111/bjd.20109
Volume184, Issue6,Pages e205-e205
Biologics (drugs injected under the skin) have revolutionized the treatment of moderate-to-severe plaque psoriasis. However, it is well known that these drugs perform differently under real-life conditions than in clinical trials, in terms of skin improvement, safety and ‘drug survival’ (the length of time until discontinuation of a drug). These issues can be influenced by both factors relating to the patient and the disease; however, it was unknown if the introduction of new biologic agents over time can have an influence on drug survival.
Recent changes in the numbers and types of lymphomas affecting the skin
doi : 10.1111/bjd.20110
Volume184, Issue6,Pages e206-e206
Lymphomas are cancers of the immune cells, the lymphocytes. These often involve the lymph nodes. However, some lymphomas are first seen in the skin and they are classified according to the type of lymphocyte, into T- and B-cell lymphomas, respectively. Yet little is known about the different types of skin lymphomas seen in populations or whether this pattern of different types changes over time. This study was carried out with the help of the French national lymphoma registry that records information about patients with lymphomas for the whole country. The lymphomas of the skin studied in this publication were those diagnosed between the years of 2005 and 2019
What proportion of basal and squamous cell skin cancers are not completely excised?
doi : 10.1111/bjd.20111
Volume184, Issue6,Pages e207-e207
Basal cell and squamous cell skin cancers (BCCs and SCCs, or ‘keratinocyte’ cancers) are the commonest cancers worldwide. They are usually treated by surgical excision – that is, by cutting them out. This is usually done in hospital but may be done by family doctors. It is important to know if such cancers are completely excised because each year they together account for 20% of all new cancers in the UK and cost the National Health Service over £180 million to treat. Incomplete excisions, where cancer cells are left behind, place an extra burden on patients and health services.
Complications of shingles
doi : 10.1111/bjd.20112
Volume184, Issue6,Pages e208-e208
Shingles, also known as herpes zoster, is a painful rash that usually appears in a stripe across the body. It is caused by the same virus that causes chickenpox. After chickenpox, the virus remains in the body. When our immune system is weakened through illness or age, the virus can reactivate to cause shingles.
Genetic studies point to novel therapeutic targets in pemphigus vulgaris
doi : 10.1111/bjd.20113
Volume184, Issue6,Pages e209-e209
Pemphigus vulgaris (PV) is a life-threatening disease that may cause severe blistering of the skin and the mucous membranes lining the mouth, nose, throat, eyes and genital area. The blisters develop in the skin as a result of the formation of autoantibodies against proteins that are responsible for the attachment of the cells to each other (cell–cell adhesion) in the tissue.
?????????????????
doi : 10.1111/bjd.20114
Volume184, Issue6,Pages e210-e210
????? (SCC) ????????????????, ??????????? 50 ?????????????? SCC, ?????????????
?????????????????
doi : 10.1111/bjd.20115
Volume184, Issue6,Pages e211-e211
1 ?????????????????????????????????????????????????????? CDSN ???? (??) ???, ????????????? (CDSN)?
?????????????????
doi : 10.1111/bjd.20116
Volume184, Issue6,Pages e212-e212
?????????????????, ????????????????????? (BPDAI) ?????????, ????????????????
?????????????
doi : 10.1111/bjd.20117
Volume184, Issue6,Pages e213-e213
????? (???????) ????????????, ?????????????? 20% ???? 3% ????????, ? 20 ?? 70 ????, ?????/??????????????????????????????, ?????????????????, ?????????????????????????
????????????????????????????????????
doi : 10.1111/bjd.20118
Volume184, Issue6,Pages e214-e214
???????? (EB) ????????, ??????, ?????????????????????? (RDEB) ????????, ??????, ???? VII ?????, ??????????????????????????????, ?????????????????, ?????????????????????????????????, ????????????????????????
???????????
doi : 10.1111/bjd.20119
Volume184, Issue6,Pages e215-e215
?????????, ????? 1·25 ??, ?????????????????????????????????????, ????????????????
?????????????????
doi : 10.1111/bjd.20120
Volume184, Issue6,Pages e216-e216
????????????????????????????????? (???) , ???????????????????????, ????????????????????????????????, ??????????????????????? (OCT)?
?????????????????
doi : 10.1111/bjd.20121
Volume184, Issue6,Pages e217-e217
???????????, ??????????????????????????????, ??????????????????????????????????????, ??????????????, ???????????????????, ???????, ???????????????????????
?????????????????
doi : 10.1111/bjd.20122
Volume184, Issue6,Pages e218-e218
????????????, ???? 0·2%-2% ???????????????????? (???????????) ??? (?????) ??, ????????????????????????????????? [??? (UV) ??] ??????????, ??????, ???????, ????????????????????????????????????
?????????????????????????
doi : 10.1111/bjd.20123
Volume184, Issue6,Pages e219-e219
???? (??????) ????????????????????????, ????, ?????????????????????????, ???????????“?????” (??????) ???????????????????????; ??, ???????????, ??????????????????????
???????????????????
doi : 10.1111/bjd.20124
Volume184, Issue6,Pages e220-e220
???????? (?????) ?????????????????, ???????????, ?????????????? T ?????? B ????????, ??????????????????, ????????????????????????, ??????????????????????????????, ??????????????????????????? 2005 ?? 2019 ???????????
????????????????????
doi : 10.1111/bjd.20125
Volume184, Issue6,Pages e221-e221
???????????? (BCC ? SCC, ?“????”?) ??????????????????????????, ??????????????????, ??????????????????????????????, ??????????????????????? 20%, ????????????????????? 1·8 ?????????, ??????, ?????????????????
????????
doi : 10.1111/bjd.20126
Volume184, Issue6,Pages e222-e222
????, ?????, ??????????????????????????????????, ??????????????????????????, ???????, ?????????
???????????????????
doi : 10.1111/bjd.20127
Volume184, Issue6,Pages e223-e223
?????? (PV) ??????????, ??????????????????????????????????????????????????????????? (??-????) ?????????????
